Uncategorized

Reata Pharmaceuticals Appoints Rajiv Patni, M.D., as Executive Vice President, Chief Research & Development Officer

Reata Pharmaceuticals, Inc., a global biopharmaceutical company focused on developing and commercializing novel therapies for patients with severe diseases, announced the appointment of Rajiv Patni, M.D., as Executive Vice President, and Chief Research & Development Officer.

Reata Pharmaceuticals Appoints Rajiv Patni, M.D., as Executive Vice President, Chief Research & Development Officer Read More »

HighField Biopharmaceuticals Receives US FDA IND Clearance for Phase 1 Trial of Immunoliposome HF158K1 for Treatment of HER2 low and HER2+ Cancers

HighField Biopharmaceuticals, a clinical stage immuno-oncology company using immunoliposomes to treat cancer, announced the U.S. Food and Drug Administration has granted clearance of the company’s Investigational New Drug application for HF158K1, a drug encapsulated immunoliposome containing doxorubicin.

HighField Biopharmaceuticals Receives US FDA IND Clearance for Phase 1 Trial of Immunoliposome HF158K1 for Treatment of HER2 low and HER2+ Cancers Read More »

Scroll to Top